GDUFA Cover Sheet Uses Old Figures To Remain “Consistent,” FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Numbers in some cases are dramatically different from more recent estimates used to calculate user fee amounts. The agency says it wanted the figures to remain consistent with a previous notice that was published before the fees were calculated.
You may also be interested in...
Backlog Backfire: FDA Sees Increase In Pending Generic Applications At Deadline
The agency was expecting many pending generic drug submissions to be withdrawn because sponsors would not want to pay the one-time backlog fee, but instead saw a substantial increase near the end of FY 2012.
Generic Drug Facilities Guidance Details Who Self-Identifies, And Who Pays Fees
An FDA draft guidance defines which generic drug manufacturers and other entities must self-report under the new user fee law and which must pay facility fees. It also outlines practical steps companies should take now to meet requirements by deadline.
ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five
The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.